PT  - JOURNAL ARTICLE
AU  - Catharina Moor
AU  - Judith Oppenheimer
AU  - Gizal Nakshbandi
AU  - Joachim Aerts
AU  - Paul Brinkman
AU  - Anke-Hilse Maitland- Van Der Zee
AU  - Marlies Wijsenbeek
TI  - Exhaled breath analysis using eNose technology in patients with sarcoidosis
AID  - 10.1183/13993003.congress-2020.4395
DP  - 2020 Sep 07
TA  - European Respiratory Journal
PG  - 4395
VI  - 56
IP  - suppl 64
4099  - http://erj.ersjournals.com/content/56/suppl_64/4395.short
4100  - http://erj.ersjournals.com/content/56/suppl_64/4395.full
SO  - Eur Respir J2020 Sep 07; 56
AB  - Background: Diagnosis of sarcoidosis can be challenging due to the variable presentation and disease heterogeneity. No simple non-invasive diagnostics tests are available in clinical practice. We hypothesized that exhaled breath analysis using eNose technology could discriminate between sarcoidosis, other interstitial lung diseases (ILD) and healthy controls.Methods: Consecutive outpatients with sarcoidosis participated. Exhaled breath data were collected using an electronic nose (SpiroNose). To assess correlation with disease activity, available serum soluble IL2 receptor (sIL-2R) measurements were categorized in low and high values. Data were analyzed using partial least squares-discriminant analysis and ROC analysis.Results: In total, 141 sarcoidosis patients were included; 51% male, mean age 54 (range 28-88), 89% had pulmonary involvement, and 48% were treated for sarcoidosis. Sarcoidosis could be reliably distinguished from healthy controls (AUC 1.0, Figure 1A) and from other ILDs (AUC 0.93, CI 0.90-0.96, Figure 1B). SpiroNose sensors discriminated between low and high sIL-2R (AUC 0.76, CI 0.63-0.89), but not between pulmonary vs. non-pulmonary sarcoidosis (AUC 0.65, CI 0.49-0.81) and treated vs. untreated patients (AUC 0.66, CI 0.57-0.75).Conclusion: Exhaled breath analysis seems a promising diagnostic tool in sarcoidosis. Further research should reveal whether eNose technology can be used as a biomarker for disease activity.FootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 4395.This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).